Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma

NCT07205731 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

95

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma (ESCC)

Interventions

DRUG: Tislelizumab is a fully humanized monoclonal antibody specific for human PD-1

Sponsor

University Hospital, Clermont-Ferrand

Collaborators

[object Object]
[object Object]